Main article

The competitive field of breast cancer prognostic assays continues to add players—all taking aim at the market current’s leader, the Genomic Health’s widely reimbursed Oncotype DX.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

September 2009 - Table of Contents

LIR September 2009 (PDF Issue)

G-2 Reports’ Recent Survey Finds Health Systems at the Forefront of Integrating Diagnostic Services

LabCorp’s Q2 Revenues Up 3.6% to $1.2 Billion; Monogram Acquisition Completed

Quest Acquires Caritas Medical Laboratories in Boston

ASCP, NCA Finalize Single Certification Agency Agreement

Quest Gets FDA Emergency Use Authorization for H1N1 Flu Test

Inside the Lab Industry: G-2 Reports Survey Finds Health Systems Leading the Way in Integrated Diagnostics

Armed with its Insight Dx, Clarient Takes Aim at Genomic Health’s Oncotype DX

Embracing Newfound Independence, Creighton Medical Labs Strives for 12% to 15% Growth in 2009

Lab Index Continues Strong Run; Up 10% over Five Weeks, 39% for Full Year 2009

Industry Buzz: OIG Recommends CMS Pursue Legislation to Revamp Payment Rates for Lab Tests